Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.
Sector ETF report for XPH
Smart Beta ETF report for XPH
Combining the actual results with the estimates for the still-to-report companies, total earnings for the healthcare sector are expected to decline 9% on revenue growth of 4.3%.
Smart Beta ETF report for XPH
Sector ETF report for XPH
Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put the spotlight on pharma ETFs, which could be the best way for investors to tap the opportunity arising from the...
Smart Beta ETF report for XPH